hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06319313, orgStudyIdInfo id: JMT101-013, briefTitle: Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-07-01, completionDateStruct date: 2027-12-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Shanghai JMT-Bio Inc., class: INDUSTRY, descriptionModule briefSummary: This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）., conditionsModule conditions: Squamous Cell Non-small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 534, type: ESTIMATED, armsInterventionsModule interventions name: JMT101, interventions name: docetaxel, interventions name: HB1801, outcomesModule primaryOutcomes measure: Overall response rate (ORR), primaryOutcomes measure: Overall Survival (OS), primaryOutcomes measure: Incidence and severity of adverse events (AE) and serious adverse events (SAE), secondaryOutcomes measure: Progression-free Survival (PFS), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of response（DOR）, secondaryOutcomes measure: JMT101 Concentrations in Plasma, secondaryOutcomes measure: Total and Free Docetaxel Concentrations in Plasma, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06319300, orgStudyIdInfo id: 20240115023245436, briefTitle: Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-19, primaryCompletionDateStruct date: 2026-03-20, completionDateStruct date: 2026-05-20, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, collaborators name: Shanghai Fifth People's Hospital,Fudan University, descriptionModule briefSummary: Our study was a single-blind, randomised, controlled, multicentre study. The study was planned to include 140 patients admitted to the general ward for subcutaneous insulin therapy, who were randomly divided into two groups in the ratio of 1:1, one group with an artificial intelligence assisted insulin dosimetry system to adjust the insulin dose to control their blood glucose, and the other group with a physician instituted insulin dosimetry adjustments to control their blood glucose. The effectiveness and safety of the system was confirmed by comparing the glycaemic control and risk of adverse events between the two groups., conditionsModule conditions: Diabetes Type 2, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: AI-assisted insulin dose adjustment model, interventions name: doctor's insulin dose adjustment, outcomesModule primaryOutcomes measure: time in target range (3.9-10.0 mmol/L ), secondaryOutcomes measure: sensor glucose, secondaryOutcomes measure: capillary blood sugar, secondaryOutcomes measure: hypoglycaemic event, secondaryOutcomes measure: hyperglycaemic event, secondaryOutcomes measure: insulin dosage, secondaryOutcomes measure: satisfaction score of doctors, secondaryOutcomes measure: Length of hospitalisation, secondaryOutcomes measure: Other/Serious Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhongshan Hospital, Fudan University, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, contacts name: Xiaoying Li, role: CONTACT, phone: +862164041990, email: li.xiaoying@zs-hospital.sh.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06319287, orgStudyIdInfo id: PRO-00125, briefTitle: Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-27, primaryCompletionDateStruct date: 2025-04-05, completionDateStruct date: 2025-07-12, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Rion Inc., class: INDUSTRY, collaborators name: Professional Education and Research Institute, descriptionModule briefSummary: A Phase 2a Multi-Center, Prospective, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Topically Applied PEP-TISSEEL in Subjects with Diabetic Foot Ulcers (DFU), conditionsModule conditions: Diabetic Foot Ulcer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Multi-center, Open Label, Randomized Controlled Clinical Trial Evaluating the Effect of PEP/TISSEEL in the Treatment of Diabetic Foot Ulcers, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: Open Label, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: PEP (Purified Exosome Product) / TISSEEL, outcomesModule primaryOutcomes measure: Wound Closure, primaryOutcomes measure: Safety, secondaryOutcomes measure: Percent Area Reduction of Wound at 12 Weeks, otherOutcomes measure: Visual Analogue Scale (VAS) for Pain over 12 weeks, otherOutcomes measure: Semmes-Weinstein Score, otherOutcomes measure: Wound-Q Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Professional Education & Research Institute (PERI), status: RECRUITING, city: Blue Ash, state: Ohio, zip: 45242, country: United States, contacts name: Charles Zelen, M.D., role: CONTACT, phone: 540-344-3668, email: cmzelen@mriedu.com, contacts name: Morgan Zelen, role: CONTACT, phone: 203-671-5915, email: mzelen@periedu.com, geoPoint lat: 39.232, lon: -84.37827, hasResults: False
protocolSection identificationModule nctId: NCT06319261, orgStudyIdInfo id: 858623, briefTitle: Efficacy of Guided Biofilm Therapy (GBT) for Treatment of Deep Periodontal Pockets., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of Baghdad, class: OTHER, descriptionModule briefSummary: the aim of the study is to evaluate the efficacy of guided biofilm therapy (GBT) for treatment of deep periodontal pockets.the objectives are1- To compare the change in the clinical periodontal parameters and microbiological parameters by using real time PCR for P. gingivalis, Aggregatibacter actinomycetemcomitans and Filifactor alocis among sites treated by GBT and conventional hand instrumentation after a period of 3 months and to assess the level of the selected periodontal pathogens in deep periodontal pockets and to estimate and compare deep periodontal pockets which need surgery after 3 months of non-surgical treatment by GBT and conventional hand instrumentation.the hypothesis is whether there are no differences in in the clinical and microbiological parameters among sites treated by GBT and conventional hand instrumentation after a period of 3 months or there are differences in in the clinical and microbiological parameters among sites treated by GBT and conventional hand instrumentation after a period of 3 months.The participants will be selected on a consecutive basis from patients referred to the Department of Periodontics, College of Dentistry, University of Baghdad.For each patient, each site will be randomly assigned to either treatment protocol:1. Sites treated with GBT.2. Sites treated with conventional manual instrumentation only., conditionsModule conditions: Periodontitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: guided biofilm therapy, interventions name: root surface debridement, outcomesModule primaryOutcomes measure: Periodontal pocket depth (PPD), secondaryOutcomes measure: Plaque index, secondaryOutcomes measure: Bleeding on probing, secondaryOutcomes measure: Relative attachment level, secondaryOutcomes measure: Changes in the bacterial load, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06319248, orgStudyIdInfo id: 24-000121, briefTitle: Use of Midodrine in Septic Shock Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2029-05-30, completionDateStruct date: 2029-07-30, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stays, less time with uncomfortable tubes, and a smoother recovery overall., conditionsModule conditions: Sepsis, conditions: Low Blood Pressure, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 270, type: ESTIMATED, armsInterventionsModule interventions name: Midodrine, interventions name: Placebo, outcomesModule primaryOutcomes measure: Time alive and without vasopressor support, secondaryOutcomes measure: Total vasopressor requirements, secondaryOutcomes measure: Central venous access duration, secondaryOutcomes measure: Cumulative fluid balance over the first 48 hours, secondaryOutcomes measure: Cumulative fluid balance up to 7 days of ICU stay, secondaryOutcomes measure: ICU Length of Stay, secondaryOutcomes measure: Hospital Length of Stay, secondaryOutcomes measure: ICU, hospital, and organ support-free days, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic Minnesota, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06319235, orgStudyIdInfo id: DUO2022_01, secondaryIdInfos id: 2022-002412-23, type: EUDRACT_NUMBER, briefTitle: Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-27, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: MB PHARMA s.r.o., class: INDUSTRY, descriptionModule briefSummary: DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S. aureus and P. aeruginosa.The primary objective of the study is to demonstrate the safety of DUOFAG® and the clinical and microbiological change within 10 weeks after the start of treatment or until healing., conditionsModule conditions: Surgical Site Infection, conditions: Staphylococcus Aureus Infection, conditions: Pseudomonas Aeruginosa Infection, conditions: Bacterial Infections, conditions: Surgical Wound Infection, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: IMP, interventions name: Placebo, outcomesModule primaryOutcomes measure: Primary endpoint - Cohort 1, primaryOutcomes measure: Primary endpoint - pooled Cohorts 1 & 2, secondaryOutcomes measure: Safety endpoints (assessed in pooled Cohorts 1 & 2), secondaryOutcomes measure: Microbiological endpoints (assessed in pooled Cohort 1 and Cohort 2), secondaryOutcomes measure: Clinical efficacy endpoints, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: St. Anne's University Hospital Brno, status: RECRUITING, city: Brno, state: Czech Republic, zip: 602 00, country: Czechia, contacts name: Dominik Maduda, MUDr., role: CONTACT, phone: +420 543 182 432, email: dominik.maduda@fnusa.cz, contacts name: Kateřina Bílá, MUDr., role: CONTACT, phone: +420 543 182 451, email: katerina.bila@fnusa.cz, geoPoint lat: 49.19522, lon: 16.60796, hasResults: False
protocolSection identificationModule nctId: NCT06319222, orgStudyIdInfo id: 23-007870, briefTitle: Implementation of a Digital Clinic for Alcohol-associated Liver Disease and Alcohol Use Disorder (DALC), acronym: DALC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, collaborators name: Ria Health, descriptionModule briefSummary: The purpose of this study is to determine whether a multidisciplinary digital clinic will improve health outcomes, reduce costs, increase access, and improve provider satisfaction.The primary aim of this study is to improve clinical outcomes in patients with ALD through the implementation of a novel digital health platform for personalized multi-disciplinary treatment of patients with ALD and AUD. Secondary aims include improvement in provider and patient-reported outcomes including satisfaction with AUD treatment., conditionsModule conditions: Alcohol Use Disorder, conditions: Liver Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: DALC Digital Clinic, outcomesModule primaryOutcomes measure: Median delta MELD-3.0 from baseline to end of study., secondaryOutcomes measure: Sustained alcohol abstinence, secondaryOutcomes measure: Reduction of Number of hospitalizations, secondaryOutcomes measure: Greater provider satisfaction in DALC arm, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic Arizona, status: RECRUITING, city: Scottsdale, state: Arizona, zip: 85259, country: United States, contacts name: Blanca C Lizaola-Mayo, MD, role: CONTACT, phone: 480-342-1094, email: dalc@mayo.edu, geoPoint lat: 33.50921, lon: -111.89903, locations facility: Mayo Clinic, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Douglas Simonetto, MD, role: CONTACT, phone: 507-284-1649, email: dalc@mayo.edu, contacts name: Camille Kezer, MD, role: CONTACT, phone: 507-284-2687, email: dalc@mayo.edu, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06319209, orgStudyIdInfo id: 2024KY023, briefTitle: Timing of Surgery and the Evolution of Postoperative Outcomes in Breast Cancer Patients Undergoing Surgical Intervention Following Recovery From SARS-CoV-2 Infection, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-03-31, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Fujian Medical University Union Hospital, class: OTHER, descriptionModule briefSummary: Perioperative SARS-CoV-2 infection significantly increases the risk of postoperative complications and mortality, while also exerting long-lasting impacts on multiple organs and systems. Due to the curtailment or cessation of non-emergency surgeries during the initial phase of the pandemic, there is a lack of evidence regarding the optimal timing and medium- to long-term postoperative outcomes of surgical intervention in breast cancer patients with prior SARS-CoV-2 infection, particularly after vaccination. We aim to investigate whether prior SARS-CoV-2 infection increases the risk of postoperative adverse outcomes in breast cancer patients and determine the optimal timing for surgical intervention during the pandemic, as well as to longitudinally assess the evolution of postoperative adverse outcomes within one year after COVID-19 and identify associated risk factors., conditionsModule conditions: Breast Cancer, conditions: COVID-19, conditions: Postoperative Complications, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 392, type: ACTUAL, armsInterventionsModule interventions name: Preoperative resolved COVID-19, outcomesModule primaryOutcomes measure: 30-day postoperative outcomes, secondaryOutcomes measure: Postoperative outcomes at the time of the initial tumor assessment after surgery, secondaryOutcomes measure: 12-month postoperative outcomes, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fujian Medical University Union Hospital, city: Fuzhou, state: Fujian, country: China, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06319183, orgStudyIdInfo id: 2023tjdxsy045, briefTitle: The Regulatory Function of Inhaled Asthma Medication Salbutamol on Thermogenesis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Tongji University, class: OTHER, descriptionModule briefSummary: In recent years, obesity and its complications have severely threatened human health. Given the limited options for obesity treatment currently available, there is an urgent need to develop new drugs and therapeutic methods to alleviate patient suffering.Mammalian adipose tissue is primarily divided into energy-storing white fat and energy-consuming brown fat. Physical activity, exposure to cold, and other factors induce the transformation of white fat into energy-consuming brown fat, a process known as adipose tissue browning. The occurrence of adipose tissue browning increases the body's energy expenditure and dissipates it in the form of heat, effectively mitigating the onset of obesity. Therefore, the regulatory mechanism of adipose tissue browning has become an important potential target for obesity treatment.The main component of asthma medication is the β2 adrenergic receptor agonist, which can act on GPCR receptors on the surface of the tracheal smooth muscle through inhalation, causing bronchial dilation and thereby alleviating asthma symptoms. Preliminary experimental results have shown that pulmonary epithelial cells can secrete protein factors that regulate the browning process of adipose tissue, and the expression of these secretory factors is regulated by the cell surface GPCR receptor signaling pathway. Therefore, our goal is to validate the regulatory effect of the asthma medication salbutamol on adipose tissue browning through inhalation administration in humans, establishing a new function for asthma medication in obesity treatment., conditionsModule conditions: Effect of Asthma Medication Salbutamol on Obesity, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Salbutamol, outcomesModule primaryOutcomes measure: Temperature of Scapular Region, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06319170, orgStudyIdInfo id: TV44749-NPC-10205, briefTitle: Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2024-12-11, completionDateStruct date: 2024-12-11, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Teva Branded Pharmaceutical Products R&D, Inc., class: INDUSTRY, descriptionModule briefSummary: The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine.A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.Another secondary objective is to characterize the pharmacokinetics of ZYPREXA.The planned duration of the study for each participant is 19 weeks., conditionsModule conditions: Schizophrenia, Schizoaffective Disorder, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 95, type: ESTIMATED, armsInterventionsModule interventions name: Olanzapine Extended Release, interventions name: Olanzapine, outcomesModule primaryOutcomes measure: Maximum observed plasma drug concentration (Cmax), primaryOutcomes measure: Area under the plasma drug concentration-time curve (AUC), primaryOutcomes measure: AUC extrapolated to infinity (AUC0-∞), secondaryOutcomes measure: Number of participants with at least 1 treatment-emergent adverse event (TEAE), secondaryOutcomes measure: Number of participants with at least 1 serious adverse event (SAE), secondaryOutcomes measure: Cmax of ZYPREXA, secondaryOutcomes measure: AUC of ZYPREXA, secondaryOutcomes measure: Apparent plasma terminal elimination rate constant (λz) of ZYPREXA, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: Teva Investigational Site 15727, status: RECRUITING, city: Hollywood, state: Florida, zip: 33024, country: United States, geoPoint lat: 26.0112, lon: -80.14949, locations facility: Teva Investigational Site 15726, status: RECRUITING, city: Marlton, state: New Jersey, zip: 08053, country: United States, geoPoint lat: 39.89122, lon: -74.92183, hasResults: False